Loading...
Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis
OBJECTIVES: To evaluate the effect of baricitinib on patient-reported outcomes (PROs) in patients with active rheumatoid arthritis (RA) and an inadequate response or intolerance to conventional synthetic disease-modifying antirheumatic drugs. METHODS: In this phase III study, patients were randomise...
Na minha lista:
| Udgivet i: | RMD Open |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BMJ Publishing Group
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5372156/ https://ncbi.nlm.nih.gov/pubmed/28405473 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/rmdopen-2016-000410 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|